Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 8.6% – Should You Buy?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s stock price traded up 8.6% during trading on Tuesday . The company traded as high as $32.40 and last traded at $33.3250. Approximately 595,851 shares traded hands during trading, a decline of 73% from the average session volume of 2,238,524 shares. The stock had previously closed at $30.68.

Wall Street Analyst Weigh In

RARE has been the subject of a number of research analyst reports. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Guggenheim lowered their price target on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a report on Friday, May 8th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Barclays dropped their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, April 29th. Finally, Weiss Ratings lowered Ultragenyx Pharmaceutical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $59.56.

Ultragenyx Pharmaceutical Stock Performance

The company has a market capitalization of $3.34 billion, a price-to-earnings ratio of -5.54 and a beta of 0.37. The business’s 50-day simple moving average is $24.99 and its 200-day simple moving average is $24.55.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same period last year, the business posted ($1.57) EPS. The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares in the company, valued at $702,129.12. This represents a 17.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 24,002 shares of company stock valued at $575,039 in the last three months. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Huntington National Bank boosted its position in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares in the last quarter. Leonteq Securities AG raised its stake in Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 1,333 shares during the period. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth $39,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 573.0% during the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 1,845 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.